TTrialPathMatch Me to Trials
← Back to trials
RecruitingHepatocellular Carcinoma (HCC)CholangiocarcinomaPancreatic Ductal Adenocarcinoma (PDAC)

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor. Circulating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.

Sponsor: City of Hope Medical Center

You may qualify if…

  • 1. Adults aged 18 years or older at the time of blood sample collection.
  • 2. Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.
  • 3. Availability of retrospective blood samples collected according to institutional protocols.
  • 4. Willingness to allow use of de-identified clinical and demographic data for research purposes.

You may not qualify if…

  • other active malignancies; insufficient sample quality/volume; recent chemotherapy/radiotherapy/surgery; any condition preventing reliable participation.

Where it's recruiting

Source: ClinicalTrials.gov · NCT07224750 · last updated 2026-07-07

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cance · TrialPath